Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the rationale behind the use of immunomodulatory therapy in the treatment of multiple myeloma and the importance of clonal hematopoiesis of undetermined potential (CHIP) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.